Clinical trials show promise in treating central n
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lym
Source: newswise.com
Abstract Number News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Abstract Number. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Abstract Number Today - Breaking & Trending Today
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® gene editing allows high...
Source: marketscreener.com
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 -- Editas Medicine, Inc. , a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral...
Source: marketscreener.com
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
IND-enabling studies expected to begin mid-2024WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taki
Source: yahoo.com
Notable Labs Presents the Design Plan for the PPMP-Enabled
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a...
Source: globenewswire.com